Literature DB >> 16715239

PET-positive fibrous dysplasia--a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery.

Klaus Strobel1, Beata Bode, Didier Lardinois, Ulrich Exner.   

Abstract

Benign bone tumors can show an increased FDG uptake in FDG-PET/CT investigations. In the presented case, an incidentally detected PET-positive asymptomatic fibrous dysplasia was initially misinterpreted as a metastasis in a patient with intimal sarcoma of the pulmonary artery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16715239     DOI: 10.1007/s00256-006-0152-y

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  27 in total

1.  The natural history of fibrous dysplasia. An orthopaedic, pathological, and roentgenographic study.

Authors:  W H HARRIS; H R DUDLEY; R J BARRY
Journal:  J Bone Joint Surg Am       Date:  1962-03       Impact factor: 5.284

2.  Imaging findings of fibrous dysplasia with histopathologic and intraoperative correlation.

Authors:  Kimberly A Fitzpatrick; Mihra S Taljanovic; Donald P Speer; Anna R Graham; Jon A Jacobson; George R Barnes; Tim B Hunter
Journal:  AJR Am J Roentgenol       Date:  2004-06       Impact factor: 3.959

Review 3.  Fibrous dysplasia.

Authors:  Selene G Parekh; Rakesh Donthineni-Rao; Eric Ricchetti; Richard D Lackman
Journal:  J Am Acad Orthop Surg       Date:  2004 Sep-Oct       Impact factor: 3.020

4.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions.

Authors:  J Aoki; H Watanabe; T Shinozaki; K Takagishi; H Ishijima; N Oya; N Sato; T Inoue; K Endo
Journal:  Radiology       Date:  2001-06       Impact factor: 11.105

5.  Infection imaging using whole-body FDG-PET.

Authors:  K D Stumpe; H Dazzi; A Schaffner; G K von Schulthess
Journal:  Eur J Nucl Med       Date:  2000-07

Review 6.  FDG PET and PET/CT imaging in lymphoma and melanoma.

Authors:  Homer A Macapinlac
Journal:  Cancer J       Date:  2004 Jul-Aug       Impact factor: 3.360

7.  F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management.

Authors:  Martin Hetzel; Coskun Arslandemir; Hans-Helmut König; Andreas K Buck; Karin Nüssle; Gerhard Glatting; Andreas Gabelmann; Jürgen Hetzel; Vinzenz Hombach; Holger Schirrmeister
Journal:  J Bone Miner Res       Date:  2003-12       Impact factor: 6.741

8.  Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography.

Authors:  Didier Lardinois; Walter Weder; Thomas F Hany; Ehab M Kamel; Stephan Korom; Burkhardt Seifert; Gustav K von Schulthess; Hans C Steinert
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

9.  Criteria and quantification of fibrous dysplasia on MDP scanning.

Authors:  M M Sathekge; R P Clauss
Journal:  Nuklearmedizin       Date:  1995-12       Impact factor: 1.379

10.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.

Authors:  Hedva Lerman; Ur Metser; Dan Grisaru; Ami Fishman; Gennady Lievshitz; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  13 in total

1.  The appearance of Mazabraud's syndrome on 18F-FDG PET/CT.

Authors:  Amit Singnurkar; J P Phancao; Deep S Chatha; Jerry Stern
Journal:  Skeletal Radiol       Date:  2007-06-23       Impact factor: 2.199

2.  Avid uptake of [18F]-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin's disease.

Authors:  C von Falck; H Rosenthal; F Laenger; J Lotz; W H Knapp; M Galanski
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-14       Impact factor: 9.236

3.  Fibrous Dysplasia Mimicking Bone Metastasis on Both Bone Scintigraphy and (18)F-FDG PET-CT: Diagnostic Dilemma in a Patient with Breast Cancer.

Authors:  Sudhir Suman Kc; Punit Sharma; Harmandeep Singh; Chandrasekhar Bal; Rakesh Kumar
Journal:  Nucl Med Mol Imaging       Date:  2012-09-15

Review 4.  PET/CT and MR imaging in myeloma.

Authors:  Michael E Mulligan; Ashraf Z Badros
Journal:  Skeletal Radiol       Date:  2006-08-17       Impact factor: 2.199

5.  PET/CT-guided biopsies of metabolically active bone lesions: applications and clinical impact.

Authors:  Bernd Klaeser; Jakub Wiskirchen; Jan Wartenberg; Thilo Weitzel; Ralph A Schmid; Michel D Mueller; Thomas Krause
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-03       Impact factor: 9.236

6.  Dual-time point PET/CT with F-18 FDG for the differentiation of malignant and benign bone lesions.

Authors:  Rong Tian; Minggang Su; Ye Tian; Fanglan Li; Lin Li; Anren Kuang; Jiancheng Zeng
Journal:  Skeletal Radiol       Date:  2009-02-10       Impact factor: 2.199

7.  The additional value of CT images interpretation in the differential diagnosis of benign vs. malignant primary bone lesions with 18F-FDG-PET/CT.

Authors:  K Strobel; U E Exner; K D M Stumpe; T F Hany; B Bode; K Mende; P Veit-Haibach; G K von Schulthess; Juerg Hodler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-20       Impact factor: 9.236

8.  F-18 FDG PET-positive fibrous dysplasia in a patient with intestinal non-Hodgkin's lymphoma.

Authors:  Mi Kim; Hyeong Su Kim; Jung Han Kim; Joo Hyun Jang; Kook Jin Chung; Mi Kyung Shin; Hee Sung Hwang; Byung Chun Kim; So Young Jung
Journal:  Cancer Res Treat       Date:  2009-09-28       Impact factor: 4.679

9.  False Positive FDG PET/CT Resulting from Fibrous Dysplasia of the Bone in the Work-Up of a Patient with Bladder Cancer: Case Report and Review of the Literature.

Authors:  Mustafa Aras; Tunc Ones; Faysal Dane; Omid Nosheri; Sabahat Inanir; Tanju Yusuf Erdil; Halil Turgut Turoglu
Journal:  Iran J Radiol       Date:  2012-12-27       Impact factor: 0.212

10.  Pulmonary artery intimal sarcoma: poor 18F-fluorodeoxyglucose uptake in positron emission computed tomography.

Authors:  Dong-Hyup Lee; Tae-Eun Jung; Jang-Hoon Lee; Dong-Gu Shin; Won-Jong Park; Jun-Hyuk Choi
Journal:  J Cardiothorac Surg       Date:  2013-03-07       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.